Peanut Allergy Clinical Trials

107 clinical trials for Peanut Allergy across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Safety of MOON101 for the Treatment of Peanut Allergy — RECRUITING · PHASE1
• Efficacy of Tezepelumab in Peanut Oral Immunotherapy — RECRUITING · PHASE2
• UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies — RECRUITING · PHASE1
• Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety — RECRUITING · NA
• Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants — RECRUITING · PHASE1
• Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients — RECRUITING · PHASE2
• Immune-supportive Diet and Gut Permeability in Allergic Children — RECRUITING · NA
• Oral Immunotherapy for Peanut Allergic Patients — RECRUITING · PHASE1
• Analysis of miRNA regulation in peanut allergic children and adolescents — RECRUITING
• VE416 for Treatment of Food Allergy — RECRUITING · PHASE1
• PEANUT ALLERGY STUDY — COMPLETED · PHASE3
• Peanut allergy study — COMPLETED · PHASE3
• Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers — COMPLETED · PHASE2
• Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy — TERMINATED · PHASE3
• Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) — COMPLETED · PHASE2
• Using Commonly Available Food Products To Treat Food Allergy — ACTIVE_NOT_RECRUITING · NA
• Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy — COMPLETED · PHASE1
• Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients — COMPLETED · PHASE1
• Food Oral Immunotherapy for Peanut Allergy — ACTIVE_NOT_RECRUITING
• Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects — ACTIVE_NOT_RECRUITING · PHASE1
• Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy — COMPLETED · PHASE1
• Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy — NOT_YET_RECRUITING · PHASE2
• Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children — OTHER
• High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety — COMPLETED · NA
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 — COMPLETED · PHASE1
• A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy — ACTIVE_NOT_RECRUITING · PHASE2
• Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants — COMPLETED · PHASE3
• Prevention of peanut allergy by early consumption - a prospective study. — OTHER
• Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy — COMPLETED · PHASE3
• Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children — COMPLETED · PHASE3
• Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT — ACTIVE_NOT_RECRUITING · NA
• Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy — COMPLETED · PHASE2
• Peanut and Tree Nut Desensitization — ACTIVE_NOT_RECRUITING · NA
• EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) — OTHER · PHASE3
• Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) — COMPLETED · PHASE3
• Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age — COMPLETED · PHASE3
• Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy — COMPLETED · PHASE2
• A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of immunotherapy in peanut-allergic patients. — NOT_YET_RECRUITING · PHASE2
• A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine — COMPLETED · PHASE1
• A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine — COMPLETED · PHASE1
• Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy — WITHDRAWN · PHASE2
• The Grown Up Peanut Immunotherapy Study — COMPLETED · NA
• Follow up of LEAP Participants and Their Families — COMPLETED
• A Randomized, Controlled Trial of Probiotic and Peanut Oral Immunotherapy (PPOIT) in Inducing Tolerance in Hong Kong Children With Peanut Allergy Compared With Oral Immunotherapy (OIT) Alone and With Placebo — OTHER · NA
• Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) — COMPLETED · PHASE2
• CNP-201 in Subjects With Peanut Allergy — TERMINATED · PHASE1
• Identification of Anaphylactogenic Antibodies in Peanut Allergy — OTHER
• Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy — COMPLETED
• Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children. — TERMINATED · NA

Refine this search